Rag2-KO/hVEGFR2

Fig1. In vivo anti-tumor response of Cyramza and Avastin in the treatment of gastric cancer PDX model(GA2419)in the immunodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)

(A)Breeding scheme for development of Rag2-KO/hKDR mice; (B) Tumor growth curves upon treatment of Cyramza and Avastin; (C) Body weight change upon treatment.

Fig2. In vivo anti-tumor response of Cyramza in thetreatment of liver cancer PDX model(LI0612)in the im-munodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)

(A)Tumor blood vesselstaining via anti-human VEGFR2 IHC; (B) Tumor growth curves upon Cyramza treatment; (C)Body weight change upon treatment.